Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131917) titled 'A Randomized, Double-Blind, Controlled Clinical Trial of Vebreltinib in Patients with IDH-Mutant Residual or Recurrent Low-Grade Glioma' on Sept. 7.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University
Condition:
IDH-mutant residual or recurrent low-grade glioma
Intervention:
Experimental Group:Vebreltinib Enteric-coated Capsules
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-07
Target Sample Size: Experimental Group:31;Control Group:31;
Countries of Recruitment:
China
To know more, visit ht...